Rapacuronium
From Wikipedia, the free encyclopedia
 |
This article or section relies largely or entirely upon a single source. Please help improve this article by introducing appropriate citations of additional sources. |
 |
|
|
Rapacuronium bromide
|
|
| Systematic (IUPAC) name | |
| [(2S,3S,5S,8R,9S,10S,13S,14S,16S,17S)- 3-acetyloxy-10,13-dimethyl-2-(1-piperidyl)-16- (1-prop-2-enyl-3,4,5,6-tetrahydro-2H-pyridin- 1-yl)-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro- 1H-cyclopenta[a]phenanthren-17-yl]propanoate |
|
| Identifiers | |
| CAS number | |
| ATC code | ? |
| PubChem | |
| Chemical data | |
| Formula | C37H61N2O4+ |
| Mol. mass | 597.891 g/mol |
| Pharmacokinetic data | |
| Bioavailability | Not applicable |
| Protein binding | Variable |
| Metabolism | Hydrolyzed to active metabolites CYP system not involved |
| Half life | 141 minutes (mean) |
| Excretion | Renal and fecal |
| Therapeutic considerations | |
| Pregnancy cat. |
C(US) |
| Legal status |
Withdrawn (U.S) |
| Routes | Intravenous |
Rapacuronium bromide (trade name Raplon, Organon) is a rapidly acting, non-depolarizing neuromuscular blocker used in modern anaesthesia, to aid and enable endotracheal intubation, which is often necessary to assist in the controlled ventilation of unconscious patients during surgery and sometimes in intensive care. As a non-depolarizing agent, it does not cause initial stimulation of muscles before weakening them.
Due to risk of fatal bronchospasm, it was withdrawn from the United States market by the manufacturer on March 27, 2001.[1]
[edit] References
- ^ Shapse, Deborah (March 27, 2001). Voluntary Market WithdrawalPDF (10.8 KiB). Organon International. Retrieved on 2007-04-02.
 |
This pharmacology-related article is a stub. You can help Wikipedia by expanding it. |
